- Home
- SNGX vs DWTX Comparison
SNGX vs DWTX Comparison
Compare SNGX & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- DWTX
- Stock Information
- Founded
- SNGX 1987
- DWTX 2012
- Country
- SNGX United States
- DWTX United States
- Employees
- SNGX N/A
- DWTX N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- DWTX
- Sector
- SNGX Health Care
- DWTX
- Exchange
- SNGX Nasdaq
- DWTX NYSE
- Market Cap
- SNGX 6.1M
- DWTX 5.9M
- IPO Year
- SNGX 1987
- DWTX N/A
- Fundamental
- Price
- SNGX $1.90
- DWTX $4.16
- Analyst Decision
- SNGX
- DWTX
- Analyst Count
- SNGX 0
- DWTX 0
- Target Price
- SNGX N/A
- DWTX N/A
- AVG Volume (30 Days)
- SNGX 29.1K
- DWTX 3.1M
- Earning Date
- SNGX 05-09-2025
- DWTX 03-31-2025
- Dividend Yield
- SNGX N/A
- DWTX N/A
- EPS Growth
- SNGX N/A
- DWTX N/A
- EPS
- SNGX N/A
- DWTX N/A
- Revenue
- SNGX $119,371.00
- DWTX N/A
- Revenue This Year
- SNGX N/A
- DWTX N/A
- Revenue Next Year
- SNGX N/A
- DWTX N/A
- P/E Ratio
- SNGX N/A
- DWTX N/A
- Revenue Growth
- SNGX N/A
- DWTX N/A
- 52 Week Low
- SNGX $1.83
- DWTX $1.62
- 52 Week High
- SNGX $14.88
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- SNGX 33.66
- DWTX N/A
- Support Level
- SNGX $2.25
- DWTX N/A
- Resistance Level
- SNGX $2.28
- DWTX N/A
- Average True Range (ATR)
- SNGX 0.11
- DWTX 0.00
- MACD
- SNGX -0.02
- DWTX 0.00
- Stochastic Oscillator
- SNGX 0.11
- DWTX 0.00
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.